Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)

21.64
Delayed Data
As of Feb 25
 -0.97 / -4.29%
Today’s Change
14.33
Today|||52-Week Range
28.81
-13.75%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$579.6M

Company Description

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Contact Information

Crinetics Pharmaceuticals, Inc.
10222 Barnes Canyon Road
San Diego California 92121
P:(858) 450-6464
Investor Relations:

Employees

Shareholders

Individual stakeholders58.89%
Other institutional34.33%
Mutual fund holders27.78%

Top Executives

There are no executives to display.